98 related articles for article (PubMed ID: 25415817)
1. Effects of ethinyl estradiol plus desogestrel on premenstrual symptoms in Iranian women.
Norouzi Javidan A; Haghollahi F; Ramezanzadeh F; Yekaninejad MS; Amiri Z; Noroozi M; Sadat Hosseini F; Azimi Nekoo E
Acta Med Iran; 2014; 52(11):837-43. PubMed ID: 25415817
[TBL] [Abstract][Full Text] [Related]
2. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins.
Ylikorkala O; Kuusi T; Tikkanen MJ; Viinikka L
J Clin Endocrinol Metab; 1987 Dec; 65(6):1238-42. PubMed ID: 2960690
[TBL] [Abstract][Full Text] [Related]
3. Contraceptive efficacy and acceptability of a monophasic oral contraceptive containing 30 microg ethinyl estradiol and 150 microg desogestrel in Latin-American women.
Comparato MR; Yabur JA; Bajares M
Adv Contracept; 1998 Mar; 14(1):15-26. PubMed ID: 9587005
[TBL] [Abstract][Full Text] [Related]
4. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate.
Charoenvisal C; Thaipisuttikul Y; Pinjaroen S; Krisanapan O; Benjawang W; Koster A; Doesburg W
Int J Fertil Menopausal Stud; 1996; 41(4):423-9. PubMed ID: 8894800
[TBL] [Abstract][Full Text] [Related]
5. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
6. [Clinical effectiveness of Marvelon].
Marianowski L; Grzechocińska B
Ginekol Pol; 1995 May; 66(5):294-6. PubMed ID: 8522228
[TBL] [Abstract][Full Text] [Related]
7. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel.
Foidart JM; Wuttke W; Bouw GM; Gerlinger C; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Jun; 5(2):124-34. PubMed ID: 10943575
[TBL] [Abstract][Full Text] [Related]
8. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
9. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
[TBL] [Abstract][Full Text] [Related]
10. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
Mansour D
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405
[TBL] [Abstract][Full Text] [Related]
11. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
[TBL] [Abstract][Full Text] [Related]
12. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
Jung-Hoffmann C; Fitzner M; Kuhl H
Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a combined oral contraceptive pill in black Zimbabwean women.
Kasule J; Mbizvo M; Makuyana D; Masona D
Cent Afr J Med; 1991 Dec; 37(12):403-9. PubMed ID: 1806254
[TBL] [Abstract][Full Text] [Related]
14. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
15. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
Vree ML; Schmidt J
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
Sangthawan M; Taneepanichskul S
Contraception; 2005 Jan; 71(1):1-7. PubMed ID: 15639064
[TBL] [Abstract][Full Text] [Related]
17. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
[TBL] [Abstract][Full Text] [Related]
18. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol.
Benagiano G
Int J Fertil; 1989 Sep; 34 Suppl():31-9. PubMed ID: 2576255
[TBL] [Abstract][Full Text] [Related]
20. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
Brown C; Ling F; Wan J
J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
